Mortality hazard associated with prescription hypnotics

Biological Psychiatry

Volumn 43, Issue 9, 1998, Pages 687-693

  Kripke, Daniel F ^a   Klauber, Melville R ^a   Wingard, Deborah L ^a   Fell, Robert L ^a   Assmus, Joseph D ^a   Garfinkel, Lawrence ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DLW) Univ of California la Jolla ^*

Author keywords

Flurazepam; Hypnotics; Mortality; Temazepam; Triazolam

Indexed keywords

CHLORDIAZEPOXIDE; DIAZEPAM; HYPNOTIC AGENT;

ARTICLE; COMORBIDITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; CHLORDIAZEPOXIDE; DIAZEPAM; DRUG UTILIZATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MORTALITY; PRESCRIPTIONS, DRUG; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 0032079811     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00292-8     Document Type: Article

References (30)

1. Adam K, Oswald I. Triazolam and platelet-aggregating factor. Lancet. 339:1992;186-187.
2. Allgulander C, Ljungberg L, Fisher LD. Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model. Acta Psychiatr Scand. 75:1987;521-531.
3. Allgulander C. Psychoactive drug use in a general population sample, Sweden Correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study . Am J Public Health. 79:1989;1006-1010.
4. Allgulander C, Nasman B. Regular hypnotic drug treatment in a sample of 32,679 Swedes Associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record-linkage . Psychosom Med. 53:1991;101-108.
5. Bruce ML, Leaf PJ, Rozal GPM, Florio L, Hoff RA. Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psychiatry. 151:1994;716-721.
6. Garfinkel L. Selection, follow-up, and analysis in the American Cancer Society prospective studies. Natl Cancer Inst Monogr. 67:1985;49-52.
7. Garfinkel L, Stellman SD. Mortality by relative weight and exercise. Cancer. 62:1988;1844-1850.
8. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics flurazepam, temazepam, and triazolam . Arch Gen Psychiatry. 46:1989;326-332.
9. Grinfeld MJ. Task force to investigate Halcion claims Upjohn libel suit draws to a close; FDA report raises new questions about drug's safety . Psychiatr Times. 11:1994;1-13.
10. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. 1985;Academic Press, New York.
11. Judd LL, Ellinwood E, McAdams LA. Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol. 10:1990;56S-67S.
12. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills Is increased mortality associated? Arch Gen Psychiatry. 36:1979;103-116.
13. Kripke DF. Chronic hypnotic use The neglected problem . Koella WP, Ruther E, Schulz H. Sleep '84. 1985;338-340 Gustav Fischer Verlag, Stuttgart.
14. Kripke DF, Hauri P, Ancoli-Israel S, Roth T. Sleep evaluation in chronic insomniacs during fourteen-day use of flurazepam and midazolam. J Clin Psychopharmacol. 10:(Suppl 4):1990;32S-43S.
15. Kripke DF, Garfinkel L. Excess nocturnal deaths related to sleeping pill and tranquilliser use. Lancet. I:1984;99.
16. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 42:1985;225-232.
17. Mitler MM, Seidel WF, van den Hoed J, Greenblatt DJ, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo A long-term simultaneous nighttime and daytime study . J Clin Psychopharmacol. 4:1984;2-15.
18. Consensus development conference statement The treatment of sleep disorders of older people . Sleep. 14:1991;169-177.
19. Sleeping Pills, Insomnia, and Medical Practice. 1979;National Academy of Sciences, Washington, DC.
20. Norusis MJ. SPSS Advanced Statistics TM 6.1. 1994;1-606 SPSS Inc, Chicago, IL.
21. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health. 80:1990;1467-1470.
22. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJI. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 316:1987;363-369.
23. Robinson RW, Zwillich CW. Drugs and sleep respiration. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 1994;603-620 W.B. Saunders, Philadelphia.
24. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc. 40:1992;787-791.
25. Shader RI, Greenblatt DJ. Triazolam and anterograde amnesia All is not well in the z-zone . J Clin Psychopharmacol. 3:1983;273.
26. Shapiro S, Slone D, Lewis GP, Jick H. Fatal drug reactions among medical inpatients. JAMA. 216:1971;467-472.
27. Solomon F, White CC, Parron DL, Mendelson WB. Sleeping pills, insomnia and medical practice. N Engl J Med. 300:1979;803-808.
28. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 319:1988;1701-1707.
29. Wysowski DK, Barash D. Adverse behavioral reactions attributed to triazolam in the food and drug administration's spontaneous reporting system. Arch Intern Med. 151:1991;2003-2008.
30. Wysowski DK, Daum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med. 151:1991;1779-1783.